

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**中國奧園集團股份有限公司**  
**China Aoyuan Group Limited**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 3883)**



**奧園健康生活集團有限公司**  
**AOYUAN HEALTHY LIFE GROUP COMPANY LIMITED**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 3662)**

## **JOINT ANNOUNCEMENT**

### **VOLUNTARY ANNOUNCEMENT APPOINTMENT OF NEW TRUSTEE BY THE CONTROLLING SHAREHOLDER**

This announcement is jointly made by China Aoyuan Group Limited (“**China Aoyuan**”) and Aoyuan Healthy Life Group Company Limited (“**Aoyuan Healthy**”) on a voluntary basis.

China Aoyuan and Aoyuan Healthy jointly announce that they have received notification from Mr. Guo Zi Wen (“**Mr. Guo**”), an executive director, the chairman and a controlling shareholder of China Aoyuan and a controlling shareholder of Aoyuan Healthy, that as a result of an internal reorganisation in the original trustee’s business operation in Singapore, on 23 August 2022, the settlors of The Golden Jade Trust, namely Mr. Guo and Ms. Jiang Miner (“**Ms. Jiang**”, spouse of Mr. Guo), completed the change of trusteeship of The Golden Jade Trust (the “**Family Trust**”, a discretionary family trust established under the laws and regulations of Singapore) which indirectly holds the equity interest in China Aoyuan and Aoyuan Healthy through Sturgeon Limited (“**Sturgeon**”) (the “**Change of Trusteeship**”).

Pursuant to the Change of Trusteeship:

- (i) J. Safra Sarasin Trust Company (Singapore) Limited. (“**Sarasin**”), the original trustee, has resigned as the trustee of the Family Trust and First Advisory Trust (Singapore) Limited (“**First Advisory**”) has been appointed as the new trustee of the Family Trust; and
- (ii) as part of the arrangement to vest the assets of the Family Trust in the new trustee, Asia Square Holdings Ltd. (“**Asia Square**”), as a nominee and trustee for Sarasin holding the equity interest in China Aoyuan and Aoyuan Healthy as trustee on trust for the beneficiaries of the Family Trust, has transferred its entire shareholding of Sturgeon to Arowana Holdings Limited (“**Arowana**”), which is a nominee of First Advisory.

The Change of Trusteeship merely involves the transfer of the entire issued share capital of Sturgeon from Asia Square to Arowana, absent any other change in the shareholding structure of China Aoyuan and Aoyuan Healthy. Neither is there any change in the ultimate beneficial ownership of the equity interest in China Aoyuan and Aoyuan Healthy following completion of the Change of Trusteeship on 23 August 2022.

A waiver was granted by the Securities and Futures Commission on 10 August 2022 pursuant to Note 6(a) to Rule 26.1 of The Code on Takeovers and Mergers and Share Buy-backs from the obligation of First Advisory (in its capacity as the trustee of The Family Trust) and Arowana (as a nominee of First Advisory) to make general offers for the shares of China Aoyuan and Aoyuan Healthy arising as a result of the Change of Trusteeship.

The directors of China Aoyuan and Aoyuan Healthy believe that the Change of Trusteeship is only incidental to the administration of the Family Trust and will not have any material impact on the control and management of China Aoyuan and Aoyuan Healthy.

At the request of China Aoyuan, trading in the shares of the China Aoyuan on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) has been suspended with effect from 9:00 a.m. on Friday, 1 April 2022 and will continue to be suspended, pending the publication of its audited annual results for the year ended 31 December 2021.

At the request of Aoyuan Healthy, trading in the shares of Aoyuan Healthy on the Stock Exchange has been suspended with effect from 9:00 a.m. on Friday, 1 April 2022 and will continue to be suspended, pending the publication of its audited annual results for the year ended 31 December 2021.

**Shareholders and potential investors of China Aoyuan and Aoyuan Healthy are advised to exercise caution when dealing in the securities of China Aoyuan and Aoyuan Healthy.**

By order of the Board  
**China Aoyuan Group Limited**  
**Guo Zi Wen**  
*Chairman*

By the order of the Board  
**Aoyuan Healthy Life Group Company Limited**  
**Guo Zining**  
*Chairman*

Hong Kong, 26 August 2022

*As at the date of this announcement, the executive directors of China Aoyuan are Mr. Guo Zi Wen, Mr. Guo Zi Ning, Mr. Ma Jun and Mr. Chen Zhi Bin; and the independent non-executive directors of China Aoyuan are Mr. Tsui King Fai, Mr. Cheung Kwok Keung and Mr. Lee Thomas Kang Bor.*

*As at the date of this announcement, the executive directors of Aoyuan Healthy are Mr. Zheng Wei and Mr. Cheng Siu Fai; the non-executive directors of Aoyuan Healthy are Mr. Guo Zining and Mr. Ruan Yongxi; and the independent non-executive directors of Aoyuan Healthy are Mr. Hung Ka Hai Clement, Dr. Li Zijun and Mr. Wang Shao.*